Matthew Jarpe

Matthew Jarpe is a Consulting Vice President of Research and Development of Regenacy Pharmaceuticals. Currently Matt is Vice President of Target Biology at KorroBio, a rare disease company focused on RNA editing. Previously, Matt served as an Associate Vice President of Biology at Acetylon Pharmaceuticals where he led the development of highly selective inhibitors for HDAC6 as well as HDAC1 and 2 in several non-oncology disease targets. Prior to joining Acetylon, Matt worked at Biogen as a Senior Scientist and at Surface Logix as an Associate Director of Biology. He received his Ph.D. from Johns Hopkins and completed his postdoctoral training at National Jewish Medical Center.